Henan Center for Diseases Control and Prevention
Zhengzhou, Henan, China
NCT Number: NCT01736709
The purpose of this study is to evaluate the immunogenicity and safety of 2012-2013 trivalent seasonal influenza vaccine in 60 healthy infants aged 6-35 months old, 60 healthy adults aged 18-60 years old, and 60 healthy older people aged > 60 years.
Looking for future studies?
Notify Me6 month–85 year
All sexes
Interventional
Phase 4
Zhengzhou, Henan, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
For adults and old people:
Inclusion criteria
Exclusion criteria
For infants:
Inclusion criteria
Exclusion criteria
trivalent seasonal influenza vaccine with 0.25 ml ⁄ vial, for infants trivalent seasonal influenza vaccine with 0.5 ml ⁄ vial, for adults and old people
Time frame: 21 days after vaccination
to evaluate the immunogenicity of the vaccine in adults and old people.
Time frame: 0-21 days after vaccination
to evaluate the safety of the vaccine in healthy infants, adults, and old people
Sinovac Biotech Co., Ltd
Industry
A Single-centered, Open-labeled, Phase 4 Study of 2012-2013 Trivalent Seasonal Influenza Vaccine
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04794829
COVID-19, Coronaviridae Infections
Bethesda, Maryland, United States
View Trial DetailsNCT07737106
Infections, Influenza
Bayan Nur, Inner Mongolia, China
View Trial DetailsNCT06518577
Infections, Influenza
Phoenix, Arizona, United States
View Trial DetailsNCT06560151
Infections, Influenza
Atlanta, Georgia, United States
View Trial Details